EMA Issues Annual Report


From DCAT Value Chain Insights (VCI)

By Regulatory News posted 05-19-2016 13:09

  

The European Medicines Agency (EMA) has published its 2015 annual report to highlight its key activities and goals.

In 2015, the agency recommended marketing authorization for 93 medicines for human use, which include 39 new active substances, and 14 medicines for veterinary use, including seven new active substances.

Approximately one in two applicants who received a positive opinion for their medicine had received scientific advice from the EMA during the development phase of their product; this figure rises to 85% for medicines containing a new active substance. Scientific advice is EMA’s key tool to promote the collection of high quality data on the benefits and risks of medicines.

For human medicines, more than 1.2 million reports on suspected side effects were recorded in EudraVigilance, the EU adverse drug reaction collection and management system, last year. Over 48,000 reports originated from patients in the European Economic Area, a 30% rise compared to 2014.

EMA’s annual report also highlights some of the main projects, initiatives and achievements in 2015 that have had a significant impact on the agency and the way it operates. Among these are: the preparation for the launch of PRIME (PRIority MEdicines) to support the development of medicines that address unmet medical needs, initiatives to help fight antimicrobial resistance and other public health threats such as Ebola, as well as the implementation of various new pieces of legislation, including a range of new activities to further strengthen the safety monitoring of medicines.

The report also contains three interviews with stakeholders and EMA representatives on topics of major interest in the area of medicines and health in 2015, including: (1) how data requirements from regulators and health-technology-assessment (HTA) bodies can be better aligned; (2) whetherthe use of big data in healthcare is a challenge or an opportunity; and (3) how immunotherapies are an important new area of cancer treatment.

Source: European Medicines Agency

0 comments
69 views


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription 

Permalink